Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY) and Merck & Company (MRK)
BioMarin Pharmaceutical Is Maintained at Outperform by SVB Leerink
BioMarin Pharmaceutical Price Target Raised to $130.00/Share From $122.00 by SVB Leerink
BioMarin Pharmaceutical Price Target Raised to $130.00/Share From $122.00 by SVB Leerink
SVB Leerink Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $130
SVB Leerink analyst Joseph Schwartz maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $122 to $130.
BioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by BMO Capital Markets
BMO Capital Markets assumed coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) in a research note published on Monday morning, The Fly reports. The brokerage issued a market per
BMO Capital Markets Begins Coverage on BioMarin Pharmaceutical (NASDAQ:BMRN)
BMO Capital Markets began coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) in a research report report published on Monday, The Fly reports. The brokerage issued a market perf
International Biotechnology Trust PLC Raises Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
International Biotechnology Trust PLC raised its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 788.6% during the third quarter, according to the company in its most r
BioMarin Pharmaceutical (NASDAQ:BMRN) Receives New Coverage From Analysts at BMO Capital Markets
BMO Capital Markets initiated coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) in a research report released on Monday morning, The Fly reports. The brokerage issued a market
BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst
BMO Capital Markets initiated coverage on BioMarin Pharmaceutical Inc (NASDAQ:BMRN) with a Market Perform rating and a price target of $107.Related: BioMarin's Growth Prospects Soar with Potential Vox
BioMarin Pharmaceuticals Started at Market Perform With $107 Stock Price Target at BMO Capital
BioMarin Pharmaceuticals Started at Market Perform With $107 Stock Price Target at BMO Capital
Loading...
No Stock Yet